The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Treatment of diabetic retinopathy: Recent advances and unresolved challenges
Open accessAbstract
Diabetic retinopathy (DR) is the leading cause of blindness in industrialized countries. Remarkable advances in the diagnosis and treatment of DR have been made during the past 30 years, but several important management questions and treatment deficiencies remain unanswered. The global diabetes epidemic threatens to overwhelm resources and increase the incidence of blindness, necessitating the development of innovative programs to diagnose and treat patients. The introduction and rapid adoption of intravitreal pharmacologic agents, particularly drugs that block the actions of vascular endothelial growth factor (VEGF) and corticosteroids, have changed the goal of DR treatment from stabilization of vision to improvement. Anti-VEGF injections improve visual acuity in patients with diabetic macular edema (DME) from 8-12 letters and improvements with corticosteroids are only slightly less. Unfortunately, a third of patients have an incomplete response to anti-VEGF therapy, but the best second-line therapy remains unknown. Current first-line therapy requires monthly visits and injections; longer acting therapies are needed to free up healthcare resources and improve patient compliance. VEGF suppression may be as effective as panretinal photocoagulation (PRP) for proliferative diabetic retinopathy, but more studies are needed before PRP is abandoned. For over 30 years laser was the mainstay for the treatment of DME, but recent studies question its role in the pharmacologic era. Aggressive treatment improves vision in most patients, but many still do not achieve reading and driving vision. New drugs are needed to add to gains achieved with available therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2023) · doi:10.1126/science · Cited by 6,063
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.047 · Cited by 562
Validation of Smartphone Based Retinal Photography for Diabetic Retinopathy Screening
Rajalakshmi, R., Arulmalar, S., Usha, M., Prathiba, V., Kareemuddin, K. S., Anjana, R. M., & Mohan, V. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138285 · Cited by 173
Peden, M. C., Suñer, I. J., Hammer, M. E., & Grizzard, W. S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.018 · Cited by 131
Cited by
Beli, E., Yan, Y., Moldovan, L., Vieira, C. P., Gao, R., Duan, Y., Prasad, R., Bhatwadekar, A., White, F. A., Townsend, S. D., et al. (2018) · Diabetes · doi:10.2337/db18-0158 · Cited by 365
Carnevali, A., Sacconi, R., Corbelli, E., Tomasso, L., Querques, L., Zerbini, G., Scorcia, V., Bandello, F., & Querques, G. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0996-8 · Cited by 263
Metadata
- Authors
- Stewart, M. W.
- Venue
- World Journal of Diabetes
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 7
- Issue
- 16
- Pages
- 333
- ISSN
- 1948-9358 (ISSN-L)
- OpenAlex
- W2511536568
- Cited by
- 158
- References
- 5
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of diabetic retinopathy: Recent advances and unresolved challenges. https://app.cochat.ai/papers/10.4239/wjd.v7.i16.333
- The paper
- Stewart, M. W. (2016). Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World Journal of Diabetes. https://doi.org/10.4239/wjd.v7.i16.333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.